Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mochida Pharma Anti-Depression Drug MHD-55 Enters Phase III Trial

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based Mochida Pharma announced that anti-depression drug MHD-55 (escitalopram) has entered Phase III trials. The company's pulmonary arterial hypertension drug MD-0701 (treprostinil), and a cell drug jointly developed with Japan Chemical Research Pharma will enter clinic trials this year. Mochida also plans to start Beselna Cream (imiquimod) clinic trials for additional applications of treating solar kerasotes. Currently imiquimod is a therapeutic agent for condyloma acuminatum. As part of its growth strategy, Mochida has been actively seeking and in-licensing products that have been marketed overseas to add to the company's product lineup. (Click here for more - Japanese language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts